Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival

Marietta Nygaard, Niels Smedegaard Andersen, Claus Ernst Moser, Gitte Olesen, Ida Marie Schjødt, Carsten Heilmann, Henrik Sengeløv

5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival'. Together they form a unique fingerprint.

Medicine & Life Sciences